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ABSTRACT: A series of new quinazoline derivatives were designed
and synthesized via a one-pot condensation reaction between isatoic
anhydride and aromatic aldehydes with anilines using aluminum
sulfate as a catalyst in refluxing ethanol. Their structures were
confirmed by their physical, IR, 1H NMR, 13C NMR, and mass
spectroscopy data and evaluated for some biological effects,
including the antioxidant and α-glucosidase inhibitory activities as
well as some in vivo hematological parameters. The ability of
synthesized compounds in the inhibition of α-glucosidase was also
investigated through the in silico study. The significant and
important changes in some hematological tests were perceived.
Notably, compound 4h showed more reducing effects on
cholesterol and triglyceride levels. This molecule certainly has the
potential to be developed as the antihyperlipemic compound. The
tested compounds, in particular, compounds 4j and 4l, were found to be uniquely reducing blood sugar levels. The entire
synthesized compounds showed the potent α-glucosidase inhibitory activity compared with acarbose as a standard material.
Amongst, the compounds 4h and 4i showed the strongest enzyme inhibitory potentials than the standard drug acarbose. There
was a good correlation between in vitro and in silico studies for ligands 4i and 4l. The majority of compounds presented a good
radical scavenging activity, though the compound 4j exhibited the strongest activity, even to the standard of ascorbic acid.
Further studies are required to determine whether these main compounds could be a potential treatment for diabetes and
hyperlipidemia diseases.
■ INTRODUCTION
Diabetes mellitus is a non-infective metabolic disorder of
multiple etiologies characterized by chronic hyperglycemia with
conflicts of the protein, carbohydrate, and fat metabolism
resulting from defects in insulin secretion, insulin action, or
both.1 Normalization of blood glucose levels, especially
postprandial hyperglycemia, is important to prevent the
complications of diabetes, which include coronary heart disease,
peripheral arteriopathy, retinopathy, neuropathy, and nephrop-
athy.2
Many natural and synthetic chemicals have been provided a
potential source of anti-diabetic special effects and are
extensively used for the treatment of diabetes mellitus in various
modern and traditional systems of medicine worldwide. A lot of
them are known to be effective against diabetes.3
In addition to adverse effects, many drugs that are presently
used for the management of type 2 diabetes are not always
satisfactory in maintaining normal levels of blood glucose and
are facing limited efficacy and tolerability.4,5
α-Glucosidase belongs to the glycosyl hydrolase 31 family of
the hydrolases, and its major function is the hydrolysis of the
terminal, non-reducing 1,4-linked α-D-glucosidase with the
release of α-D-glucose. α-Glucosidase has drawn special
attention of the pharmaceutical research community since, in
earlier studies, it was revealed that the inhibition of its catalytic
activity resulted in the retardation of glucose absorption and
decrease in postprandial blood glucose level.2 α-Glucosidase
inhibitors play an important role to delay or inhibit the digestion
or absorption of carbohydrates and suppress the postprandial
hyperglycemia.6 Hence, they have broad aspects and many
potentially expedient in the management of type 2 diabetes.
Heterocyclic compounds are of special interest to the
medicinal chemists due to their unique biological properties.2
Nitrogen-containing heterocyclic compounds are the most
abundant and integral scaffolds that occur entirely in a variety
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of synthetic drugs, bioactive natural products, and pharmaceut-
icals.7 The presence of N-heterocycles as an essential structural
motif in a variety of biologically active substances has stimulated
the development of the novel technologies and strategies for
their synthesis. Among the N-containing heterocycles, quinazo-
linone is a building block of approximately 200 naturally
occurring alkaloids isolated to date from a number of plants,
microorganisms, and animals.7 The first quinazolinone was
synthesized in the late 1860s from cyanogens and anthranilic
acid to give 2-cyanoquinazolinone.8
On a quest to find further potential quinazolinone-based
drugs, various substituted quinazolinones have been synthe-
sized.9 The quinazolinone derivatives have shown various
biological activities such as antimalarial,10 anticancer,11 anti-
HIV,12 antimicrobial,13 anti-inflammatory,14 antitubercular,15
antihypertensive,16 and cholinesterase inhibition17 activities.
This broad spectrum of effects has been further facilitated by the
synthetic versatility of quinazolinones, which authorizes the
generation of numerous structurally various molecules.18 The
antidiabetic19 and antioxidant13 activities of these compounds
were also appraised.20,21
Considering the importance of these compounds, several
methods have been revealed for the synthesis of 2,3-
dihydroquinazolin-4(1H)-ones. They are usually synthesized
by three-component reactions of aldehydes, isatoic anhydrides,
primary amines, or ammonium salts, in the presence of
numerous catalysts, under different circumstances.22−25 Some
of these reagents or catalysts are cerium(IV) sulfate,26 (Cu-
CNTs),27 choline chloride in the presence of malonic acid,28
silica-bonded propyl-S-sulfonic acid (SBSSA),29 silica-bonded
N-propyl sulfamic acid (SBNPSA),30 and Al(H2PO4)3.
31 Some
of these methods have limitations such as long reaction time,
high-temperature reaction, side reactions producing a mixture of
products and complex separation, and purification methods. In
the current study, we developed the synthesis of 2,3-
dihydroquinazolin-4(1H)-ones in the presence of aluminum
sulfate (Al2(SO4)3·6H2O) as a catalyst in ethanol. Furthermore,
pyrazol-quinazolinones as the new derivatives of quinazolinones
were synthesized by replacing aromatic aldehyde with pyrazole-
4-carbaldehyde (compounds 4g−4l). Moreover, our catalyst-
basedmethod has benefits such as having less reaction time, high
performance, and environmental compatibility and being a low-
cost catalyst and nontoxic.
Free radicals are reactive chemicals that are short-lived species
having one or more unpaired electrons. They induce injury to
organism cells by a small increase in the unpaired electron
resulting in cell biomolecules oxidation.32
One possible hypothesis in diabetes is that the disease state
leads to an increase in active oxygen species production. In
addition to the starring role of oxidative stress in the onset of
diabetes, it seems to play a key role in chronic complications of
the disease. It has been reported that the free radical scavengers
are effective in avoiding diabetes in animal models.33−36
However, recent shreds of evidence have revealed that first-
line therapy for cardiovascular disease prevention and the most
important lipid-lowering drugs such as statins can increase the
risk of new-onset diabetes.37,38 It is assumed to have a direct
correlation between antidiabetic and antioxidant potentials of
compounds. A number of studies revealed that a compound
exhibiting a higher glucose-lowering effect appears to have a
good antioxidant potential as well.39−42 Moreover, it has been
alleged that some drugs can alter normal hematological
values.43,44 Hence, the hematological parameters could be a
crucial factor in their toxic effect evaluations;45 though, it is
believed that some antioxidant agents can combat oxidative
stress and improve the hematological status.46 Clinically, it is
needed to develop the new therapeutic approaches with the
novel generation of drugs lacking these side effects. Here, in this
study, we are reporting the synthesis of some new derivatives of
quinazolines and their hematological and antioxidant activities,
Table 1. Optimization of the Reaction Conditionsa
entry catalyst (mmol) solvent conditions time (min) yield (%)b
1 ethanol reflux 600
2 0.01 ethanol R.T. 80 32
3 0.01 ethanol 40 °C 80 60
4 0.02 ethanol 55 °C 80 72
5 0.02 ethanol 65 °C 80 74
6 0.02 ethanol reflux 80 78
7 0.02 n-hexane reflux 80 70
8 0.02 water 80 °C 80 20
9 0.02 methanol/water (50:50) 80 °C 80 53
10 0.02 ethyl acetate reflux 80 60
11 0.04 ethanol reflux 80 82
12 0.06 ethanol reflux 80 88
13 0.07 ethanol reflux 80 89
14 0.06 ethanol reflux 80 55c
15 0.006 g ethanol reflux 80 43d
aReaction conditions: isatoic anhydride (1 mmol), 5-chloro-3-methyl-1-phenylpyrazole-4-carbaldehyde (1 mmol), aniline (1 mmol), and solvent (5
mL). R.T., room temperature. bIsolated yield. cThe reaction was catalyzed by AlCl3 (0.06 mmol).
dThe reaction was catalyzed by acidic alumina
(0.006 g).
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α-glucosidase inhibitory potential, and molecular docking
studies.
■ RESULTS AND DISCUSSION
The catalytic activity of aluminum sulfate (Al2(SO4)3·6H2O)
was investigated in the synthesis of 2,3-dihydroquinazolinones
via a one-pot three-component condensation reaction between
aromatic aldehydes and isatoic anhydride with aniline
derivatives. In a preliminary study, the reaction of isatoic
anhydride and 5-chloro-3-methyl-1-phenylpyrazole-4-carbalde-
hyde with aniline was selected as a model reaction in refluxing
ethanol (Table 1). To illustrate the need of Al2(SO4)3·6H2O for
this condensation, we examined the model reaction in the
absence of Al2(SO4)3·6H2O in refluxing ethanol (Table 1, entry
1). The results exhibit clearly that Al2(SO4)3·6H2O is an
effective catalyst for this transformation, and in the absence of
Al2(SO4)3·6H2O, the reaction did not take place even after 10 h.
Also, when we used other aluminum species such as aluminum
trichloride and acidic alumina as a catalyst, the corresponding
product was obtained in low yields (Table 1, entries 14 and 15).
As indicated in Table 1, the best results were obtained with 0.06
mmol of Al2(SO4)3·6H2O in refluxing ethanol (Table 1, entry
12).
In order to synthesize 2,3-dihydroquinazolinones, the
reaction between aromatic aldehydes (2) and isatoic anhydride
with aniline derivatives (3) was investigated under optimized
conditions. As shown in Table 2, aniline derivatives such as 4-
hydroxyaniline, 3-chloroaniline, and 4-methylaniline and those
treated with aromatic aldehydes and isatoic anhydride and
corresponding products were obtained in good to high yields.
The novel classes of pyrazol-quinazolinones were synthesized by
replacing 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbalde-
hyde instead of aromatic aldehyde. These new derivatives were
achieved in good to high yields under optimized reaction
conditions.
According to Table 2, the desired product was well reached by
aromatic aldehydes with the electron donor and acceptor
substituents under reaction conditions. On the other hand, this
reaction was carried out well and raced up by aromatic amines
due to their high nucleophilic power. The recommended
mechanism to provide the 2,3-dihydroquinazolin-4(1H)-ones
by Al2(SO4)3·6H2O as the catalyst is shown in Figure 1. First, the
catalyst activated the carbonyl isatoic anhydride group to get the
compound ready for an amine group attack. This is due to the
C−O bond breaking in the carbonyl group and forming the
intermediate (i). Consequently, a CO2molecule and catalyst left
the compound, and an intermediate was attained (ii). Then, the
catalyst-activated aldehyde group was attacked by an ammo-
nium nitrogen lone pair and compound (iii) was obtained. To
summarize, the product was obtained by hydrogen displacement
and ring formation.
Spectral Data for New Compounds.
2-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-phenyl-
2,3-dihydroquinazolin-4(1H)-one (4g) (Table 2, Entry 7).
Isolated yield = 88%. White color. mp 216−218 °C. IR (KBr):
Table 2. Synthesis of 2,3-Disubstituted-2,3-
Dihydroquinazolin-4(1H)-ones by Reaction of Isatoic
Anhydride with Aldehydes and Primary Aminesa
aReaction conditions: isatoic anhydride (1 mmol), aniline (1 mmol),
aldehyde (1 mmol), and solvent 5 mL. bIsolated yield. Car*. = 5-
chloro-3-methyl-1-phenylpyrazole-4-carbaldehyde.
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3305 (N−H), 1684 (NCO) cm−1. 1H NMR (300 MHz,
DMSO-d6) δ (ppm): 2.23 (s, 1H), 6.47 (s, 1H), 6.75−6.81 (m,
2H), 7.19−7.22 (m, 3H), 7.28−7.35 (m, 6H), 7.45 (t, J = 7.4
Hz, 1H), 7.50 (t, J = 7.8 Hz, 2H), 7.72 (d, J = 7.8 Hz, 1H); 13C
NMR (75 MHz, DMSO-d6) δ (ppm): 13.8, 66.6, 114.8, 115.2,
115.6, 118.1, 125.2, 126.8, 127.5, 128.3, 128.5, 128.9, 129.0,
129.8, 134.2, 137.8, 140.3, 148.4, 149.0, 163.9. Anal. Calcd. for
C24H19ClN4O; C, 69.48; H, 4.62; Cl,8.54; N, 13.50%. Found C,
69.17; H, 4.73; N, 13.21%. MS (m/z): 414 (M+), 323 (base
peak).
2-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(p-
tolyl)-2,3-dihydroquinazolin-4(1H)-one (4h) (Table 2, Entry
8). Isolated yield = 78%. Yellow color. mp 190−192 °C. IR
(KBr): 3289 (N−H), 1630 (NCO) cm−1. 1H NMR (300
MHz, CDCl3) δ (ppm): 2.32 (s, 3H), 2.39 (s, 3H), 6.40 (s, 1H),
6.73 (d, J = 7.8 Hz, 1H), 6.92 (t, J = 7.4 Hz, 1H), 7.08−7.14 (m,
4H), 7.30−7.50 (m, 7H), 8.05 (d, J = 7.8 Hz, 1H); 13C NMR
(75MHz, CDCl3) δ (ppm): 13.9, 21.1, 67.0, 114.4, 114.7, 116.6,
119.7, 124.9, 127.1, 128.5, 129.1, 129.3, 129.5, 129.6, 133.8,
136.7, 137.2, 137.7, 146.7, 149.0, 164.3. Anal. Calcd. for
C25H21ClN4O; C, 70.01; H, 4.94; Cl, 8.26; N, 13.06%. Found C,
69.68; H, 4.90; N, 12.72%. MS (m/z): 428 (M+), 429 (M+ + 1,
base peak).
2-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(4-hy-
droxyphenyl)-2,3-dihydroquinazolin-4(1H)-one (4i) (Table 2,
Entry 9). Isolated yield = 70%. White color. mp 236−238 °C. IR
(KBr): 3305 (N−H), 1615 (NCO) cm−1. 1H NMR (300
MHz, DMSO-d6) δ (ppm): 2.24 (s, 3H), 6.73 (s, 1H), 6.65−
6.82 (m, 4H), 7.00 (d, J = 8.4 Hz, 2H), 7.30−7.37 (m, 4H),
7.44−7.56 (m, 3H), 7.74 (d, J = 6.9 Hz, 1H), 9.50 (brs, 1H); 13C
NMR (75 MHz, DMSO-d6) δ (ppm): 13.8, 66.8, 114.7, 115.2,
115.5, 115.8, 117.9, 125.1, 126.8, 128.5, 128.9, 129.3, 129.8,
131.4, 134.0, 137.8, 148.4, 149.0, 156.6, 164.0. Anal. Calcd. for
C24H19ClN4O2; C, 66.90; H, 4.44; Cl, 8.23; N, 13.00%. Found
C, 66.56; H, 4.49; N, 12.74%. MS (m/z): 430 (M+), 431 (M+ +
1, base peak).
2-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(4-
chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one (4j) (Table
2, Entry 10). Isolated yield = 63%. Orange color. mp 219−221
°C. IR (KBr): 1613 (NCO) cm−1. 1H NMR (300 MHz,
CDCl3) δ (ppm): 2.38 (s, 3H), 6.43 (s, 1H), 6.76 (d, J = 8.1 Hz,
1H), 6.98 (t, J = 7.5 Hz, 1H), 7.12−7.16 (m, 1H), 7.22−7.29
(m, 4H), 7.36−7.52 (m, 6H), 8.05 (dd, J1 = 7.0 Hz, J2 = 1.2 Hz,
1H), ; 13C NMR (125 MHz, DMSO-d6) δ (ppm): 13.3, 66.1,
114.4, 114.7, 115.1, 117.7, 124.7, 126.4, 127.0, 127.8, 128.1,
128.4, 128.5, 129.3, 133.8, 137.3, 139.8, 147.9, 148.5, 163.4.
Anal. Calcd. for C24H18Cl2N4O; C, 64.15; H, 4.04; Cl, 15.78; N,
12.47%. Found C, 63.79; H, 4.13; N, 12.11%. MS (m/z): 449
(M+, base peak), 450 (M+ + 1), 451 (M+ + 2).
Figure 1. Mechanism of the synthesis of 2,3-dihydroquinazolin-4(1H)-ones.
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2-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(2,4-di-
methylphenyl)-2,3-dihydroquinazolin-4(1H)-one (4k) (Table
2, Entry 11). Isolated yield = 80%. White color. mp 202 °C. IR
(KBr): 3283 (N−H), 1612 (NCO) cm−1. 1H NMR (400
MHz, CDCl3) δ (ppm): 2.16 (s, 6H,Me), 2.22 (s, 3H,Me), 6.41
(s, 1H, CH), 6.75−6.81 (m, 2H, Ar), 6.91 (d, J = 6.4 Hz, 1H,
Ar), 6.99 (s, 1H, NH), 7.05 (d, J = 6.4 Hz, 1H, Ar), 7.28−7.34
(m, 4H, Ar), 7.43−7.53 (m, 4H, Ar), 7.73 (d, J = 6.4 Hz, 1H,
Ar). 13C-NMR (125MHz, DMSO-d6) δ (ppm): 13.3, 18.9, 19.2,
66.0, 114.3, 114.9, 115.3, 117.5, 124.6, 124.8, 124.9, 126.3,
128.0, 128.4, 128.5, 129.3, 133.5, 134.8, 136.2, 137.2, 137.3,
147.8, 148.4, 163.2. Anal. Calcd. for C26H23ClN4O2; C, 70.50;
H, 5.23; Cl, 8.00; N, 12.65%. Found C, 70.21; H, 5.34; N,
12.43%. MS (m/z): 442 (M+), 57 (base peak).
2-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-(3,4-di-
methylphenyl)-2,3-dihydroquinazolin-4(1H)-one (4l) (Table
2, Entry 12). Isolated yield = 78%.White color. mp 201−203 °C.
IR (KBr): 3299 (N−H), 1645 (NCO) cm−1. 1H NMR
(500MHz, DMSO-d6): 2.15 (s, 6H), 2.21 (s, 3H), 6.40 (s, 1H),
6.74−6.78 (m, 2H) ,6.88−6.90 (m, 1H), 6.98 (s, 1H), 7.04 (d, J
= 8.0 Hz, 1H) ,7.27−7.33 (m, 4H), 7.43−7.46 (m, 1H), 7.50−
7.53 (m, 2H) , 7.71 (d, J = 8.0 Hz, 1H). 13C NMR (75 MHz,
DMSO-d6): 13.8, 19.4, 19.7, 66.5, 114.8, 115.3, 115.8, 118.0,
125.1, 125.3, 126.8, 128.5, 129.0, 129.8, 134.1, 136.3, 136.7,
137.7, 137.8, 148.4, 148.9, 163.8. Anal. Calcd. for
C26H23ClN4O2; C, 70.50; H, 5.23; Cl, 8.00; N, 12.65%. Found
C, 70.16; H, 5.32; N, 12.48%. MS (m/z): 442 (M+), 279 (base
peak).
Biological Activities. From the newly synthesized com-
pounds, to study the donor−acceptor substituent effects on
some biological activities, the compounds 4g, 4h, 4i, 4j, 4k, and
4l were selected.
Antioxidant Activity. Recently, antioxidants have attracted
much attention in relation to oxidative stress and radicals, cancer
prophylaxis and therapy, and longevity.47 To study the free
radical scavenging ability of the synthesized compounds (4g−
4l), the DPPH [diphenyl-(2,4,6-trinitrophenyl)iminoazanium]
assay was used. The DPPH assay method is based on reduction
of DPPH, a stable free radical.48 The results are presented in
Table 3.
All compounds presented the good radical scavenging in a
dose-dependent manner at concentrations of 0.2−1.0 μM
compared to the control group (Table 3), while the compound
4j showed strong inhibitory activity, stronger than ascorbic acid
as a standard. This compound showed a significant inhibitory
effect with the increase in concentrations (p < 0.05) but not
statistically significant between concentrations of 0.8 and 1 μg/
mL. This is probably due to the greater involvement of chlorine
substitution in free radical stabilization in the relevant doses.
The second potent compound was 4i (80.07 ± 0.77 to 86.47 ±
0.27%). This was followed by compounds 4k, 4l, 4g, and 4h in
different concentrations. In these four compounds, the
inhibition values showed a transient increase, with a mild
gradient in a dose-dependent manner.
Themost and least inhibition values were associated with 4-Cl
and 4-Me substrates, respectively, and then, the higher
inhibitory activities were observed in rings with −Cl as an
acceptor substitute in comparison to Me as the donor. This may
be due to the stability of the electric charge throughout the
component DPPH by the acceptor agent (Cl), where, inMe, the
substrate charge becomes unstable after mixing two molecules.
The formed free radical is well stable owing to the proper
location of chlorine for the electron-withdrawing effect in the
para position. This belongs to the inductive effect of electron-
withdrawing groups. However, in our other structures with
electron-donating groups, the stereoelectronic effect of the
phenyl ring is the main reason for the competition between the
inductive effect and electron cloud deployment. Electron cloud
deployment further demonstrates its effect on free radical
stability.
Generally, the antioxidant capacity depends on several
particular structural properties, such as the electronegativity,
position, and number of functional groups in the antioxidant
molecule. Therefore, the choice of models with particular
functional groups for measuring the antioxidant capacity
influences the results. Among the abovementioned contents,
the higher antioxidant content of compound 4k rather than 4h
can be due to the position of functional groups in the molecule
Table 3. Inhibition Percent (%) Values of Different Concentrations (μg mL−1) of the Tested Substances (4g−4l) and Ascorbic
Acid (AA) as a Standard Antioxidant Obtained from the DPPH Scavenging Assay
compound
conc. (μg mL−1) 4g 4h 4i 4j 4k 4l AA
0.2 20.71 ± 0.2 11.42 ± 0.03 80.07 ± 0.77 79.9 ± 0.9 67.72 ± 0.2 60.14 ± 0.1 53.13 ± 0.7
0.4 20.32 ± 0.2 11.44 ± 0.02 81.18 ± 0.5 87.68 ± 0.7 67.80 ± 0.3 60.19 ± 0.2 61.22 ± 0.7
0.6 20.51 ± 0.1 11.46 ± 0.02 83.9 ± 0.1 93.58 ± 1 67.87 ± 0.1 60.25 ± 0.2 69.18 ± 1
0.8 21.16 ± 0.1 11.48 ± 0.04 85.62 ± 0.3 99.37 ± 0.7 67.95 ± 0.2 60.30 ± 0.1 88.47 ± 0.9
1.0 20.62 ± 0.5 11.50 ± 0.07 86.47 ± 0.27 102 ± 2 68.03 ± 0.1 60.35 ± 0.2 98.03 ± 2
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4k.49 As shown in Figure 2, the phenyl ring in compound 4k has
less free rotation around the C−N bond than the 4h structure.
This is due to the steric congestion of methyl in the ortho
position and its inhibition rather than that of the carbonyl group.
Consistent with the result of Ichikawa et al., it would appear that
the ring A in compound 4k is fixed and its electron cloud
belonging to the π orbital of the aromatic ring can more easily
overlap and stabilize the single electron of DPPH.50
It is a good approximation to think of the geometry of free
radicals as a shallow pyramid, which allows for overlap of the
half-filled p orbital with adjacent π bonds. Also, the stereo-
electronic effect is defined by the preferred mode of the
approach of a radical as it bonds to the π-electron system of an
alkene group. When comparing our results to Broggi et al., it
must be pointed out that single electrons can overlap with the
adjacent p orbitals as shown in Figure 3.51 To prove this,
molecules 4k and 4l were compared. Comparison between
ligands showed that ligand 4l exhibits lower inhibition
percentage due to its more free rotation.
Free radicals are stabilized by adjacent groups with lone pairs.
Nitrogen, oxygen, and some halogens have lone pairs of
electrons and can donate electron density to the half-empty p
orbital, which stabilizes the free radical system that is a
hyperconjugation effect. This is an interaction between a half-
empty orbital (the free radical) and a filled orbital (the lone pair
of oxygen). Probably for this reason, the inhibitory percentage of
molecule 4i is high.
The excess free radicals circulating in the body oxidize the
low-density lipoproteins (LDL), making them potentially lethal;
the excess free radicals can also accelerate aging processes and
have been linked to other very serious pathologies, such as brain
stroke, diabetes mellitus, rheumatoid arthritis, Parkinson’s
disease, Alzheimer’s disease, and cancer.47,52 The essential
features of oxidation via a free radical-mediated chain reaction
are initiation, propagation, branching, and termination steps.53
The process may be initiated by the action of outside agents such
as heat, light, or ionizing radiation or by chemical initiation
involving metal ions or metalloproteins. There is great attention
in antioxidants, predominantly in those planned to prevent the
presumed harmful properties of free radicals in the human body
as well as the deterioration of fats and other ingredients of
foodstuffs.53
Compound 4j was found to be an excellent antioxidant agent.
It is an appropriate candidate for further development as
antioxidants. Further studies are required to determine whether
compound 4j could be a potential treatment for some notable
diseases caused by oxidative stress, such as neural disorders, lung
diseases, cancer, heart disease, and diabetes.
Studies on the antioxidant effects of similar compounds are
limited. According to Tong et al., acortatarins A, one of the two
novel alkaloids with a naturally unusual morpholine motif
isolated from the rhizome of Acorus tatarinowii, could
significantly inhibit reactive oxygen species production in
high-glucose-stimulated mesangial cells in a dose- and time-
dependent manner.54 Similarly, Chiou et al. have shown that the
synthetic compound magnolamide from pyrrole-2,5-dicarbalde-
hyde definitely inhibited CuSO4-induced oxidation of human
LDL (IC50 = 9.7 μM), with similar activity to the antioxidant
standards probucol and resveratrol.55
Hematological Study in Vivo. A summary of significant
changes in the levels of some hematological parameters in mice
blood samples, comprising the red blood cells (RBC), white
blood cells (WBC), hemoglobin concentration (Hb), mean
corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration
(MCHC), hematocrit (HCT), platelet (PLT), red cell
distribution width (RDW), albumin (ALB), creatinine (Cr),
triglyceride (TG), cholesterol (CLST), and glucose (GLU),
separately after intraperitoneal administration of two 0.3 and 0.5
mM doses of three quinazoline derivatives (4h, 4j, and 4k),
compared with the negative (normal) and positive control
(diabetic) groups is shown in Table 4.
At one glance, the measurable changes in hematological
parameter values were observed compared to their control
groups (Table 4).
According to Lawal et al., the erythrocyte parameters
comprising the RBC, Hb, MCH, MCHC, and RDW are
appropriate indicators of the circulatory erythrocyte levels and
offer the valuable indexes of the bone marrow capacity to
produce the RBC following the administration of drugs, toxins,
or plant extracts.56 In line with the ideas of Mishra and Tandon,
it can be revealed that a significant increase in Hb (4j), RBC (4h
and 4j), and MCHC (4h and 4k) following treatment with two
0.3 and 0.5 mM doses of quinazoline derivatives may indicate
the stimulation of erythropoiesis by these chemicals.57
According to the results, a dramatically significant increase
was observed in the serum cholesterol and TG levels between
the diabetic and the normal groups (p < 0.5). These factors were
remarkably improved dose-dependently after administration of
two doses of all quinazoline derivatives compared to the diabetic
group (p < 0.05). However, the compound 4h has shown more
reducing effects on cholesterol and TG concentrations (p <
0.05). This may be due to steric effect and the smaller size of this
molecule than other molecules, which makes it more reactive.
These molecules certainly have the potential to be developed as
antihyperlipemic compounds.
Hyperlipidemia is the presence of high levels of lipids in the
blood. It is a metabolic derangement caused by many diseases,
especially cardiovascular diseases.58 There are many classes of
lipid-lowering agents. All these drugs have different mechanisms
Figure 2. Comparison of the free rotation between molecules 4h and
4k.
Figure 3. Intermolecular interaction between single electrons with the
adjacent p orbitals.
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of action. However, these lipid-lowering drugs possess various
side effects. Hence, research is continuing to discover novel
agents that are more potent and safe.59 The quinazolinone
derivatives are found to have various biological activities,
including anti-hyperlipidemic activities.58,59
Kurogi et al. showed that the quinazolines and 4(3H)-
quinazolinones are hypolipidemic agents. They have reduced
the triglyceride and total cholesterol levels.60 According to
Kusunoki et al., the lipoprotein lipase (LPL) activator NO-1886
(ibrolipim) shows antiobesity effects in high-fat-induced obese
rats.61 This quinazoline derivative decreased the levels of plasma
triglycerides, nonesterified free fatty acids, and glucose as well as
the enhancement of LPL activity in animal skeletal muscle.61
Promising results obtained from the subchronic study of Refaie
et al.62 revealed the antihyperlipidemic effect of quinazolinone
compounds by inhibition of dietary cholesterol absorption and/
or intestinal human acyl-CoA: cholesterol acyltransferase
(ACAT) activity. The significant reductions in serum total
cholesterol, triacylglycerol levels, and cholesterol ester were
observed in their study.61 Similarly, a decrease in serum
cholesterol and TG levels of some synthetic novel quinazoline
derivatives, as well as significantly increased in the serum HDL
level has shown by Kathiravan et al.63
Moreover, it was found that all verified compounds showed a
significant decrease in creatinine level as compared with the
diabetic control group (p < 0.05).
According to very recent studies, the most important lipid-
lowering drugs have even caused diabetes mellitus disease.37,64 A
meta-analysis study by Wang et al. showed that statin therapy
and the relative reduction in LDL are associated with a risk of
new-onset diabetes.38 Previously, Simonen et al. have
demonstrated that diabetes is evidently associated with high
cholesterol synthesis and mild elevated serum and lipoprotein
triglyceride levels.65 They have verified that the insulin-resistant
fat cells release the extensive free fatty acids to the circulation. In
their study, lipoprotein synthesis had also increased. Their
findings showed a direct association between blood sugar levels
and cholesterol synthesis.65 Therefore, the offering of such drugs
with potentially concurrent beneficial effects on both diseases in
the future of drug discovery is really promising.
Administration of a derivative (4j) resulted in higher levels of
WBC in these treated groups compared to the nondiabetic
control group (p < 0.05), but not more than the diabetic control
group, while it was significantly reduced in diabetic mice that
received the compound 4k compared to the control groups at
two levels of concentrations. All molecules had significant
differences with normal and diabetic groups (p < 0.05). This did
not include the molecule 4h at a concentration of 0.5 μM
compared to the normal control group.
The highest mean RBC level was observed in the presence of
the compound 4h, compared to the other molecules and both
control groups (p < 0.05). In this parameter, all desired
molecules in both concentrations had a significant difference
compared to the diabetic group. This result ties well with
previous studies that reported the significant increase in
response to the administration of chemicals.56,57
However, the molecule 4k had a significant difference
compared to the normal group. Then, the influence of the 2,4-
di-Me substituents in the molecule 4k could be remarkable.
From the perspective of the association between antioxidant
and hematological effects, the study of Kelkar et al.46 revealed
that antioxidants can combat oxidative stress and improve the
hematological status such as Hb and RBC levels. Others have
shown that the chemicals with antioxidant activities can improve
the hematological parameters.66,67
The deleterious effects of diabetes mellitus on hematological
parameters were also reported by Oyedemi et al..68
Serum creatinine level is the most common index of renal
function. As indicated, administering the desired compounds
significantly decreased the creatinine levels compared to the
diabetic groups in the animal model. In line with the finding of
Tsompos et al., we speculate that our antioxidant agents may
improve renal function by increasing creatinine excretion.69 The
effects of antioxidants on the creatinine level were in accordance
with the results of Dennis and Witting.70 Hence, introducing a
novel uncomplicated drug with the revealed effects can be a
great aid for these patients.
The HCT (in 0.3 mM) and Hb levels were decreased
significantly alone in the group that received the compound 4k.
Except for the molecule 4j, at a dose of 0.5 μM, all confirmed
molecules had significant differences compared to the diabetic
group (p < 0.05). No statistically significant changes were
observed in the HCT levels in the mice exposed to the
compound 4j at a dose of 0.3 μMcompared to the normal group.
Table 4. Significant Changes, in Some Hematological Parameters and Electrolyte Levels (Mean± SD), of Mice Blood Samples,
after Administration of Two 0.3 and 0.5 mM Doses of Quinazolinone Derivatives Compared with Control Groups
compound
4h 4j 4k
parameters 0.3 0.5 0.3 0.5 0.3 0.5 diabetic control normal control
WBC (103/mm3) 5.3 5.6 7.6 8 3.15 2.8 8.3 5.6
RBC (106/mm3) 9.05 9.92 9.34 9.17 8.05 7.92 8.74 9.18
HB (g/dl) 14.5 ± 0.1 14.2 ± 0.25 14.8 ± 0.34 14.8 ± 0.3 8.0 ± 0.2 10.9 ± 0.1 13.3 ± 0.2 14.5 ± 0.2
HCT (%) 37.1 ± 0.1 37.9 ± 0.1 38.6 ± 0.1 39.6 ± 0.08 18.1 ± 0.1 34.9 ± 0.2 38.5 ± 0.1 37.3 ± 0.1
MCV (μm3) 40.9 40.1 40.2 39.9 44.9 44.1 44.1 40.6
MCH (ρg) 15.8 ± 0.1 15.5 ± 0.23 15.7 ± 0.2 15.5 ± 0.03 15.8 ± 0.1 15.8 ± 0.1 15.3 ± 0.1 15.8 ± 0.07
MCHC (g/dL) 44.0 ± 0.2 41.2 ± 0.1 38.6 ± 0.2 38.2 ± 0.1 44.0 ± 0.2 41.2 ± 0.2 34.7 ± 0.1 38.9 ± 0.1
PLT (103/mm3) 5884 10000 1350 1326 5884 10000 1072 1336
RDW (%) 21.8 ± 0.03 23.6 ± 0.02 22.5 ± 0.01 22.2 ± 0.02 12.2 ± 0.01 24.8 ± 0.01 24.3 ± 0.02 22.2 ± 0.01
Alb (g/dL) 2.7 ± 0.04 2.7 ± 0.02 2.9 ± 0.02 2.8 ± 0.01 2.8 ± 0.07 2.8 ± 0.03 3.3 ± 0.03 2.8 ± 0.03
UA (μM) 61 ± 3 62 ± 1.5 65 ± 2 65 ± 2 66 ± 2.7 67 ± 3.3 71.9 ± 2.7 64 ± 3.2
Chlst (mg/dL) 64 ± 3.2 58 ± 6 66 ± 1.4 62 ± 2.8 64 ± 3.2 60 ± 6 79 ± 2.4 73 ± 5
TG (mg/dL) 127 ± 1.5 109 ± 0.7 123 ± 3 116 ± 3 127 ± 2.5 121 ± 4 191.2 ± 5.2 131 ± 4.2
Cr (mg/dL) 0.41 ± 0.05 0.4 ± 0.05 0.41 ± 0.07 0.41 ± 0.09 0.45 ± 0.05 0.42 ± 0.05 0.85 ± 0.03 0.45 ± 0.02
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The significant increases were observed in the MCHC and PLT
levels in groups that received 4k and 4h compounds compared
to the diabetic group (p < 0.05).
A number of chemicals and natural products have been
scientifically tested and reported possessing the ability to
decrease blood glucose levels of normal and/or diabetic
animals.61−74
The mean blood glucose concentrations were determined to
be 70 ± 2 and 57 ± 2 (mM) in the control group in doses of 0.3
and 0.5 mM and 365 ± 4 and 524 ± 6 in the diabetic group,
respectively. Table 5 shows that treatment of diabetic mice with
six quinazoline derivatives (4g−4l) caused a significant and
dose-dependent reduction in blood sugar levels compared to
both control groups (p < 0.05).
Administration of both doses of compounds 4j and 4l resulted
in a significant collapse in blood glucose levels as much as below
the limit of quantification of the method (LOQ = 20 mM). Such
a reduction was also perceived in compound 4k at a dose of 0.5
mM. These tested compounds were found to be uniquely
reducing sugar levels.
As a whole, our hematological study revealed that the
quinazoline derivatives are safe from the viewpoint of
hematotoxicity and can even recover the hematological side
effects associated with diabetes mellitus.
α-Glucosidase Inhibitory Activity. α-Glucosidase is a
catabolic enzyme that regulates the body’s plasma glucose levels
by providing energy sources to maintain healthy functioning. α-
Glucosidase inhibitor drugs reduce the glucose level of blood as
a strategy for the treatment of type 2 diabetes.75
All the synthesized compounds showed the potent inhibitory
potential ranging from (2.6± 0.1, 2.5± 0.1 μM) to (29.3± 0.5 ,
25.4 ± 0.6 μM) in 0.3 and 0.5 mM of samples, respectively,
compared to acarbose as a standard with IC50 = 34.4 ± 0.3 and
30.1 ± 0.2 μM. The IC50 levels in all the test compounds
decreased compared to that of the standard drug (p < 0.05).
Also, as shown in Table 6, the IC50 values in both concentrations
of the samples (0.3 and 0.5 mM) were dose-dependently
decreased in all tests and standard compounds. Amongst all the
synthesized compounds, the derivatives 4h, 4i, and 4l showed
the strongest enzyme inhibitory potential than the standard drug
acarbose.
In a series of recent studies, some quinazoline derivatives were
reported as extremely active α-glucosidase inhibitors for
controlling hyperglycemia.76−78 In the study of Gurram et al.,
a series of 21 synthesized novel quinazoline derivatives have
been screened against α-glucosidase.76 Among all the tested
molecules, seven compounds showed <20 μM activity to α-
glucosidase, and six compounds showed exhibited excellent
inhibition activities when compared to acarbose (6.2 μM), with
the IC50 values between 3.2 and 8.6 μM.
76 These results are
comparable to our study results.
These findings are also consistent with the research study of
Babar et al., showing that a synthetic quinazoline compound has
a potent inhibitory effect toward α-glucosidase with an IC50
value of 150.4 ± 1.9 μM compared to acarbose (336.9 ± 9.0
μM) as the standard.79 This is consistent with what has been
found in the previous study of Garlapati et al..80 They
investigated the 25 synthesized quinazoline compounds to
biological assays against α-glucosidase and found that three
compounds were potentially active as α-glucosidase inhibitors
and showed activity with IC50 values of <10 μM. They have
demonstrated that these main compounds are excellent
candidates for further pharmacological applications.
Docking Study. To find the correlation between the
experimental and computational data, the docking study of the
compounds was performed against α-glucosidase enzyme
inhibitory activities. According to the binding site in α-
glucosidase, the desired compound would be able to form the
different types of molecular bonds with the α-glucosidase
structure and making it a favorable binding site. The estimated
binding energies (kcal/mol) of the 10 clusters are presented in
Table 7.
Among the 10 clusters, the preeminent results for each
molecule from the perspective of their binding energies (kcal/
mol), Ki (μM), and other conformation information were
selected for further examinations (Table 8).
Our docking results showed that all compounds have more
stability than acarbose as the control group (Table 8). The best
conformations from the docking procedure with the best-scored
pose and the lowest binding energy (about −6.1 to −8.85 kcal/
mol) were selected for these ligands (4g−4l). From the docking
results, compound 4i with the OH substituent at the para
position exhibited the least binding energy with α-glucosidase
that shows the overcoming of hydrogen bonding rather than
other polar effects in these compounds. Table 9 shows the
number of different types of molecular bonds between ligands
and the α-glucosidase.
At this stage of understanding, it can be construed that the
high binding affinity of compounds 4i and 4l is related to the
greater number of the van der Waals and hydrogen bond
between the enzyme and ligand (Figure 4). According to Table
9, π−anion, π−cation, and π−π interactions are less important.
We speculate that the low affinity of the molecule 4j with the
enzyme may be due to the steric effect of chlorine than other
substitutions in the para position. Furthermore, the electron-
withdrawing (EWG) and the electron-donating groups (EDG)
Table 5. Mean Blood Glucose Levels (in mM) in Diabetic Mice Treated with Quinazoline Derivatives (4g−4l)
compound
conc. (mM) 4g 4h 4i 4j 4k 4l diabetic control normal control
0.3 65 ± 2 44 ± 1 44 ± 1 <LOQa 29 ± 1 <LOQ 365 ± 4 70 ± 2
0.5 27 ± 1 22 ± 1 <LOQ <LOQ <LOQ <LOQ 524 ± 6 57 ± 2
aLimit of quantification.
Table 6. α-Glucosidase Inhibition of Quinazoline Derivatives
(4g−4l) Compared with Acarbose as a Standard
IC50 (μM)
no. conc. (0.3 mM) conc. (0.5 mM)
4g 29.3 ± 0.5 25.4 ± 0.6
4h 2.6 ± 0.1 2.5 ± 0.1
4i 2.96 ± 0.8 2.62 ± 0.5
4j 15.9 ± 0.3 11.7 ± 0.3
4k 21.5 ± 0.4 18.2 ± 0.2
4l 3.03 ± 0.5 3.0 ± 0.1
acarbose 34.7 ± 0.3 30.1 ± 0.2
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had almost similar effects (4i > 4l > 4g > 4h > 4j > 4k >
acarbose). The higher energy in acarbose may be due to the
absence of π interactions in its structure (Figure 4).
The involved residues in the close interaction are listed in
Table 10.
When comparing the results of Figure 4, it must be pointed
out that themolecules 4i and 4lwith the single substituent in the
para position had the highest number of amino acid residues (20
amino acids). Also, the number of amino acids in 4h, 4k, and
acarbose is the same. Generally, the number of residues increases
from 4h to 4l (4i and 4l > 4g > 4j > 4h, 4k, and acarbose).
The comparison between the amino acid residues of the
molecules and acarbose showed that the highest share of amino
acids was related to the compound 4g with 13 amine acids
(Phe144, Phe163, Tyr63, Asp326, His103, Asn324, Phe282,
Asn258, Ala200, Asp199, Val100, Glu256, and Arg197).
Phe163, Asn258, Asp199, Glu256, and Ala200 were common
in all compounds similar to acarbose, where the two amino acids
Arg411 and Leu258 found in acarbose have not existed in any of
the relevant molecules.
■ CONCLUSIONS
In conclusion, the quinazoline derivatives from pyrrole-2-
carbaldehyde and amines, particularly molecules 4i and 4l,
were a potent and amazing anti-α-glucosidase agent with strong
binding to enzyme that correlated well with the experimental
data. There was a good association between in vitro and in silico
studies. The hematological study of the desired compounds
revealed that the quinazoline derivatives are safe from the
viewpoint of hematotoxicity and seem to improve the
hematological abnormalities associated with diabetes mellitus
in the animal model. In addition, these findings provide
additional information about the molecule 4h that certainly
has the potential to be developed as antihyperlipemic drugs
because of its excellent reducing effects on cholesterol and TG
levels. The majority of compounds, particularly the compound
4j, presented the exceptional radical scavenging. This conclusion
follows from the fact that the antioxidant agents improved the
hematological parameters. This is desirable for future work after
the safety evaluation of the compounds.
■ EXPERIMENTAL SECTION
Materials and Methods. General. All chemicals were
purchased from the Fluka, Merck, and Aldrich chemical
companies. All products were characterized by comparison of
their FT-IR (Fourier transform infrared), 1H NMR, and 13C
NMR spectroscopic data.
The study was permitted by the Medical Ethics Committee of
Bushehr University of Medical Sciences and Health Services,
Bushehr-Iran, and a written informed consent was obtained
from all subjects of study. All animal works were carried out in
accordance with the National Ethical Guidelines for Animal
Research in Iran (2005) under a project license, which was
approved by the Animal Care and Use Committee of the Persian
Gulf, according to the protocol PG/FS/CHDO2. All animals
were kept in a climate-controlled environment at 25 °Con a 12 h
light/12 h dark cycle. Adequate food and water were available
during all experimental processes, and all efforts were made to
minimize suffering.
1-Aryl-5-chloro-3-methyl-1H-pyrazole-4-carbaldehyde
General Preparation. First, 64 mL of phosphoryl chloride (0.7
M) was added dropwise to 23 mL of ice-cold dimethylforma-
mide (0.3 M). After adding 17.5 g of 3-methyl-1-phenyl-5-
pyrazolone (0.1 M), the mixture was heated under reflux
conditions for 1 h. At room temperature, a volume of 600 mL of
cold water was added to the mixture and filtered and then
recrystallized from ethanol.
2,3-Dihydroquinazolin-4(1H)-ones General Synthesis
Method. To a mixture of isatoic anhydride (1 mmol), 5-
Table 7. Binding Energies of the Compounds Based on Their Clusters (kcal/mol)
binding energy (kcal/mol)
compound 1 2 3 4 5 6 7 8 9 10
4g −8.02 −8.36 −7.75 −7.75 −6.71 −7.77 −7.93 −7.31 −6.41 −6.37
4h −6.92 −6.90 −6.87 −6.31 −6.11 −5.91 −5.83 −5.83 −5.81 −4.87
4i −8.85 −8.83 −8.8 −8.64 −8.46 −8.42 −8.02 −7.85 −6.03 −6.02
4j −6.32 −6.22 −6.15 −6.04 −6.05 −5.77 −5.77 −5.18 −5.18 −5.11
4k −6.10 −6.07 −5.96 −5.94 −5.89 −5.83 −5.67 −5.67 −5.41 −4.79
4l −6.46 −6.46 −8.25 −6.73 −7.14 −6.88 −7.83 −7.49 −7.79 −7.29
Table 8. Docking Results of Synthesized Compounds against α-Glucosidase
compound Ki (μM) binding energy (kcal/mol) ligand efficiency intermolecular energy torsional energy electrostatic energy unbound energy
4g 2.66 −7.61 −0.25 −8.2 0.6 0.03 −1.64
4h 8.43 −6.92 −0.22 −7.52 0.6 0.03 −1.72
4i 0.326 −8.85 −0.29 −9.74 0.89 0.0 −1.59
4j 23.39 −6.32 −0.2 −6.91 0.6 0.02 −1.62
4k 33.82 −6.10 −0.19 −6.7 0.6 0.08 −1.33
4l 0.903 −8.25 −0.26 −8.84 0.6 −0.11 −1.46
acarbose 0.67 0.02 −5.89 6.56 −0.73 −11.41
Table 9. Number of Different Types of Molecular Bonds
between Ligands and the α-Glucosidase
compound
hydrogen
bonding
van der
Waals
π−anion and π−
cation π−π
π
alkyl
4g 10 3 2 6
4h 7 4 3 4
4i 1 13 2 1 7
4j 12 2 6
4k 8 1 2 5
4l 3 10 1 3 3
acarbose 2 11 1
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chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (3) (1
mmol), and aniline derivatives (1 mmol) in 5 mL of ethanol was
added to 0.027 g of Al2(SO4)3·6H2O and heated under reflux
conditions. The reaction progress was monitored by thin-layer
chromatography (TLC). After completing the reaction, the
solvent was removed. The mixture was cooled to precipitate the
corresponding pyrazol-quinazolinone products, which were
finally purified by column chromatography on silica gel using
n-hexane/ethyl acetate as an eluent.
Antioxidant Activity. The antioxidant activities (AA %) of
the products were performed by the free radical DPPH (1,1-
diphenyl-2-picrylhydrazyl; Fluka, Buchs, Switzerland) according
to the Buritz and Bucar method.81 Dispersing delocalized
electrons all over themolecule makes DPPH a free stable radical.
The delocalized electron causes a deep purple color at λmax = 517
nm.When a solution of DPPH ismixed with a substrate acting as
a hydrogen atom donor, a stable, nonradical form of DPPH is
obtained with a simultaneous change in color from violet to pale
yellow. Briefly, 50 mL from each of the methanolic solutions
(4h, 4j, and 4k), in different dilutions of 0.2, 0.4, 0.6, 0.8, and 1.0
μg/mL, was mixed with 5 mL of the DPPH methanolic solution
(0.004%). The DPPH solution was kept in a dark place. After 30
min incubation, the absorbances of the samples were measured
using a Cecil Aquarius CE7200 double-beam spectrophotom-
eter (Cecil, England) at 517 nm. The methanolic solutions of six
compounds and DPPH were used as blank and control samples,
respectively. Inhibition (I) of the DPPH radical in percent (%)
was calculated by the following equation
I A A A(%) ( )/ 100blank sample blank= − ×
where Ablank is the absorbance at 517 nm after a period of 30 min
without the addition of the antioxidant and Asample is the
absorbance in the presence of the antioxidant.
An Inhibition value versus different concentrations diagram
was used to calculate IC50. Results are expressed as the
antioxidant amount that reduces the DPPH concentration to
50% of the initial value.82 All measurements were repeated three
times.
Hematological Study In Vivo. For some hematological
studies in vivo of the compounds (4h, 4j, and 4k), including the
blood glucose levels, 40 male mice (weighing approximately 20
± 2 g) from the animal house of the Bushehr University of
Medical Sciences, Bushehr-Iran, were randomly divided into
eight groups (n = 5). After fasting for 18 h, the experimental
diabetes was induced by intraperitoneal (ip) injection of 0.5 mL
of a single dose of 50 mg/kg aloxan. After 5 days of the aloxan
injection, for monitoring of glucose, the blood tail was measured
using a glucometer (Bionime Rightest GM 300, Switzerland),
and animals with a blood glucose value of over 200 mg/dL were
assumed to be diabetic.83 Furthermore, animals were observed
for general signs of diabetes like polydipsia, hyperphagia, and
polyuria during the study. This group of animals was considered
as a positive control group. Six groups of animals have separately
received 0.5 mL of the compounds (4h, 4j, and 4k) at the doses
of 10 and 20 (mg/kg, ip) for 1 week. Also, one group of animals
was given saline as a negative control group. For hematological
parameters in vivo, the animals were anesthetized with diethyl
ether. A blood sample of each animal was collected by cardiac
punctures into both EDTA (10%) tubes for directly
hematological tests and without anticoagulant tubes for
biochemical examinations. The performance evaluations of
hematological parameters include RBC, WBC, Hb, MCV,
MCH, MCHC, PLT, RDW, and HCT and were performed
using the Sysmex XE-5000 hematology analyzer. All tests were
done in triplicate, and the data were expressed as mean ± SD.
Statistical analysis was carried out using the Kruskal−Wallis test.
p < 0.05 was considered statistically significant. For chemical
analysis of serum electrolytes, a portion of free anticoagulant
blood samples, which were previously described, were
centrifuged at 600g for 15 min and the supernatant was
separated as the serum. Serum albumin, uric acid, glucose,
triglyceride, and cholesterol were also measured.
Figure 4. Docking of the six synthesized compounds (4g−4l) and
acarbose (as the standard molecule) with α-glucosidase enzyme.
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α-Glucosidase Inhibitory Activity. The α-glucosidase
inhibitory activities of the compounds were evaluated
spectrophotometrically using a previously published method
with some modifications.75 Briefly, for each compound, 20 μL of
0.5 U/mL of α-glucosidase solution was mixed with 120 μL of
100 mM potassium phosphate buffer (pH 6.9) and 10 μL of the
sample (0.3 mM, in buffer). Acarbose was used as a standard
inhibitor. Each mixture was separately incubated at 37 °C for 15
min. The enzymatic reaction was initiated by adding 20 μL of the
substrate 4-nitrophenyl-α-D-glucopyranoside (pNPG) (5 mM)
in the buffer.
Themixture was repetitively incubated at 37 °C for 15min. At
that point, the reaction was stopped by adding 80 μL of sodium
carbonate solution (0.2 M). The enzyme-free mixture was also
used as a blank sample. Finally, the absorbance was measured at
405 nm. The blank sample in which the substrate was changed
with 50 μL of the buffer was analyzed to accurately determine
the background absorbance. The positive control sample
(acarbose) was prepared to contain 10 μL of DMSO (dimethyl
sulfoxide) instead of test samples. The percentage of enzyme
inhibition was calculated as (1 − B/A) × 100, where A
represents the absorbance of control without test samples and B
represents the absorbance in the presence of test samples.
Analyses were carried out in triplicates, and the results were
expressed as mean ± SD.
Computational Details. The binding affinities between the
identified structures (in addition to acarbose as the control
compound) and the active site of the α-glucosidase receptor
were examined through docking studies using the AutoDock
Tools 1.5.6 Workspace.84 Interactive visualization and analyses
of the molecular structures were carried out in the Discovery
Studio R2 64-bit Client system. The three-dimensional (3D)
structure of α -glucosidase was downloaded from the RCSB
Protein Data Bank (PDB). The chemical structures of the
ligands were obtained from the PubChem compound database.
Open Babel was used to convert the PDB files to the PDBQT
file. For docking analysis, PDB coordinates of the target proteins
and ligands were optimized. Geometry optimization is
performed using Gaussian 09 (adding missing residues).
These coordinates had minimum energy and a stable
conformation.
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